Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Chimeric antigen receptor (CAR) T cells are generated from healthy donors (allogeneic) or patient-derived T cells (autologous). After the T cells are expanded and genetically modified, they are reinfused into the patients. CAR T cell therapies use genetically engineered T cells to specifically target tumor cells, which offer a novel approach to cancer therapy. This innovative therapeutic approach has achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors.
Gamma-Delta (γδ) T cells are a distinct subset of T cells based on variable chains in the T cell receptor (TCR) protein complex. CAR γδ T cells at Creative Biolabs are engineered by incorporating a second-generation CAR into γδ T cells using the non-viral Sleeping Beauty (SB) transposon or CAR lentiviral transduction technology.
Cytokine-induced killer (CIK) cells are a heterogeneous population of polyclonal T cells that acquire phenotypic and cytotoxic properties of natural killer (NK) cells through the cultivation process, becoming so-called T-NK cells. CAR-CIK cells at Creative Biolabs are engineered by incorporation of second-generation CAR into PBMC-derived CIK cells using the non-viral SB transposon or CAR lentivirus transduction technology.
As a starting source for CAR T cells, induced pluripotent Stem Cells (iPSCs) is an attractive approach to developing "off-the-shelf" CAR T-cell therapies. Creative Biolabs incorporates a second-generation CAR into iPSCs-derived T cells using lentiviral transduction technology to engineer the CAR-iT cells.
Adoptive transfer of regulatory T cells (Tregs) can suppress lymphocytes against other antigens in the local microenvironment without destroying normal cells expressing the target antigen. Creative Biolabs incorporates a second-generation CAR into PBMC-derived Treg cells using lentiviral transduction technology to design CAR-Treg cells.
Jurkat cells are an immortal human leukemic T cell line widely used to examine T cell activation and signaling mechanisms. Creative Biolabs presents a cost-efficient and rapid method for evaluating CARs in human Jurkat T cells, which is anticipated to accelerate the discovery and improve the quality of candidate CAR-T cell therapies for future clinical applications.
Stem cell memory T (TSCM) cells have high self-renewal ability, greater persistence, and comparable anti-tumor immunity in contrast to effector T (Teff) cells and effector memory T (Tem) cells. Recently, TSCM has served as a favorable type of source for ACT Adoptive cell therapy. Creative Biolabs specializes in engineering TSCM-based CAR T cells, incorporating special CAR into enriched TSCM cells to realize the enhancement of in vivo expansion and long-term remissions.
Animal cells serve as a critical integral part of CAR research, which can be widely used to engineer CAR animal cells. Creative Biolabs is committed to providing a variety of animal cell lines for CAR immunotherapy studies to treat refractory hematologic malignancies and solid tumors.
In the tumor microenvironment (TME), macrophages are the most abundant immune cells playing a key immunomodulation role in tumorigenesis and progression. Promisingly, the generation of CAR-engineered macrophage cell therapies (CAR-MA) will bring great therapeutic potential for intractable solid tumors. Leveraging years of experience in the field of CART, we are convinced to provide CAR-MA products according to the special needs of global customers.
Creative Biolabs offers wide range CAR cells type to meet your different needs at every step of your CAR research. Our cells have access to authentication which is vital importance for you to ensure your research can be trusted and reproducible. We follow the highest manufacturing standards and use the most reliable procedures in process control (IPC) and quality control (QC) to verify and authenticate every cell line.
Please browse the target below to find the right CAR cell product for you.
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION